Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:disease
|
| gptkbp:associatedWith |
gptkb:BRCA1_mutation
|
| gptkbp:characterizedBy |
aggressive clinical behavior
|
| gptkbp:diagnosedBy |
immunohistochemistry
|
| gptkbp:hasHigherRiskOf |
recurrence
|
| gptkbp:hasNoApproved |
targeted therapy (as of 2024)
|
| gptkbp:hasPoorerPrognosisThan |
other breast cancer subtypes
|
| https://www.w3.org/2000/01/rdf-schema#label |
TNBC
|
| gptkbp:isLessResponsiveTo |
hormonal therapy
HER2-targeted therapy |
| gptkbp:isMoreCommonIn |
African American women
younger women |
| gptkbp:lacksExpressionOf |
HER2
estrogen receptor progesterone receptor |
| gptkbp:standsFor |
gptkb:triple-negative_breast_cancer
|
| gptkbp:studiedBy |
immunotherapy
|
| gptkbp:subjectOf |
clinical trials
|
| gptkbp:subspecies |
gptkb:cancer
|
| gptkbp:treatment |
chemotherapy
|
| gptkbp:bfsParent |
gptkb:Peter_Engel_Productions
|
| gptkbp:bfsLayer |
6
|